The World’s First Companion Prognostics: Redefining the Standard of Transplant Care
The integration of the predictive pre-transplant PIRCHE scores with dd-cfDNA screening transitions transplant care from reactive treatment to proactive, precision surveillance.
Validated by over 200 peer-reviewed publications and 1,000,000+ patient cases, Pirche delivers proven clinical evidence for all solid organ and hematopoietic stem cell transplantations.
Why Choose PIRCHE in Combination with dd-cfDNA Screening?
By combining molecular risk stratification with real-time injury detection, clinicians can personalize monitoring, intervene earlier, and significantly extend long-term graft survival.
This risk-stratified workflow enables a personalized treatment plan based on thepatient's unique immunological "risk profile."
Step 1: Baseline Assessment of Risk Profile
Establish the PIRCHE Score before or at the time of transplantation with regard to the specified donor-recipient match to categorize the patient’s baseline immune susceptibility.
Step 2: Stratified Monitoring
Align dd-cfDNA screening frequency with the patient’s immunological risk profile, ensuring compliance with MolDx guidelines while maximizing detection.
Step 3: Data-Driven Action
If dd-cfDNA levels rise, clinicians utilize the baseline PIRCHE score alongside other advanced TxPredictor modules (such as OPM, RAMP or Tmem) to determine whether an immediate biopsy is required or if a targeted adjustment in immunosuppression is appropriate.
By bundling PIRCHE and dd-cfDNA, transplant centers move beyond generalized protocols to a new standard of precision medicine - minimizing risk while maximizing graft half-life.
Latest research highlights the potential of PIRCHE in tailoring immunosuppression and advancing allogeneic immunotherapy development in oncology and autoimmunity.
Reach out to us to explore how you can leverage PIRCHE in your projects and clinical practise.
Our partners
Transplant Medicine
Compatibility between a recipient and a donor is at the core of success in solid-organ and bone marrow transplantation.
PIRCHE focuses on predicting how well the recipient's immune system will recognize and respond to the donor organ based on HLA epitopes.
Minimize Graft versus Host Disease
Guiding immunosuppressive therapy
Optimizing biomarker monitoring
Donor selection
Technology
TxPredictor
Our state-of-the-art platform, TxPredictor, merges genetic typing with real-time, AI-supported immunological simulations, enabling clinicians to make precise, personalized medical decisions.
The Pirche TxPredictor platform uses T and B cell epitope predictors, allowing clinicians and laboratories to interact with their patient’s tissue compatibility data like never before. Running on a high-performance cloud infrastructure, it combines real time analysis with clear user interfaces.
By leveraging standard clinical lab results and seamlessly integrating with leading laboratory IT systems, we provide a plug-and-play solution that transforms patient care.
Highlights & features
Absolute and relative immunologic risk quantification
Low resolution HLA typing support
Real time & cloud based
Low turnaround time
Integration with major HLA vendors’ software
No maintenance
Cell Therapy
PIRCHE epitope matching reduces the risk of immune rejection, by identifying donors whose cells are less likely to be recognised as foreign. This is crucial in allogeneic cell therapy where mismatched donor cells can lead to immune-mediated destruction of the therapeutic cells.
Pirche can help
Identify optimal
‘off-the-shelf’ therapy
Minimize Graft versus Host Disease
Optimize therapy efficacy and safety
